Characteristics of long-term survivors with Myelodysplastic syndrome treated with 5-azacyditine. Results from the Hellenic 5-azacytidine Registry.

Publication date: Available online 28 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Panagiotis T. Diamantopoulos, Vasiliki Pappa, Argiris Symeonidis, Ioannis Kotsianidis, Athanasios Galanopoulos, Helen Papadaki, Achilles Anagnostopoulos, George Vassilopoulos, Panagiotis Zikos, Eleftheria Hatzimichael, Maria Papaioannou, Aekaterini Megalakaki, Maria Kotsopoulou, Panagiotis Repousis, Maria Dimou, Eleni Solomou, Charalampos Pontikoglou, Georgios Kyriakakis, Dimitrios Tsokanas, Menelaos-Konstantinos PapoutselisAbstractHypomethylating agents have altered the prognosis of myelodysplastic syndrome (MDS) so that long-term survival is now a feasible goal of treatment.We analyzed data from patients with MDS treated with 5-azacytidine recorded in the Hellenic 5-azacytidine registry. We divided patients, based on their survival after 5-azacytidine initiation (OST), in groups of long-term survivors (Q3 and P90 group with OST above the 3rd quartile and the 90th percentile of the whole group, respectively) and short-term survivors comprising the remaining patients, and compared the characteristics between the groups.The study included 626 patients (157 in the Q3 group and 63 in the P90 group). Categorization per the IPSS, IPSS-R, and WPSS was found to predict long-term survival, while multivariate analysis revealed that response to 5-azacytidine was the strongest predictor of long-term survival. Nevertheless, patients with hematologic improvement (HI) and stable dis...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research